Yabao Pharmaceutical Co., Ltd. and Lilai new diabetes drug ly26082047-august clinical application

Ren Wuxian, chairman of Yabao Pharmaceutical Co., Ltd., said on the sidelines of the two sessions of the pharmaceutical industry today that the research and development of diabetes drugs cooperated by the company and Lilly is smooth, and it is expected to apply to the State Drug Administration for clinical trials in July August this year The above diabetes drugs, ly2608204, a new diabetes drug jointly developed by Yabao pharmaceutical and Lilly, are glucokinase agonists, which can promote insulin secretion and reduce glucose production In July 2014, Yabao pharmaceutical announced a strategic partnership with Lilly to jointly develop Lilly's new diabetes drug ly2608204 The drug has completed clinical phase I and a large number of preclinical work in the United States According to the agreement signed by both parties, Yabao pharmaceutical will have the right to develop and use new drugs in China, be responsible for the financing and development of the project, while Lilly will be responsible for other markets and have the right to buy back products.